Standard BioTools (NASDAQ:LAB – Get Free Report) will likely be announcing its Q3 2026 results before the market opens on Tuesday, November 3rd. Analysts expect the company to announce earnings of ($0.02) per share and revenue of $18.80 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:00 PM ET.
Standard BioTools (NASDAQ:LAB – Get Free Report) last released its earnings results on Wednesday, August 5th. The company reported ($0.07) EPS for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.06). Standard BioTools had a net margin of 100.36% and a negative return on equity of 7.57%. The business had revenue of $20.10 million for the quarter, compared to the consensus estimate of $20.80 million.
Standard BioTools Trading Down 0.9%
Shares of NASDAQ LAB opened at $0.60 on Tuesday. The business’s 50 day moving average price is $0.68 and its 200-day moving average price is $0.94. Standard BioTools has a fifty-two week low of $0.59 and a fifty-two week high of $1.72.
Analysts Set New Price Targets
Separately, Weiss Ratings cut Standard BioTools from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday, August 7th. Two equities research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Standard BioTools has a consensus rating of “Reduce” and an average price target of $1.35.
Get Our Latest Stock Report on Standard BioTools
Standard BioTools Company Profile
Standard BioTools Inc (NASDAQ: LAB) develops and supplies technologies, instruments and consumables used by researchers and biopharmaceutical companies to analyze biological systems. Its portfolio supports applications in proteomics, genomics, single-cell analysis, mass cytometry and spatial biology.
The company’s offerings include the SomaScan protein profiling platform, which measures large numbers of proteins from biological samples, as well as CyTOF mass cytometry systems for high-dimensional single-cell analysis.
Further Reading
- Five stocks we like better than Standard BioTools
- A Solid Margin Story Means the Sell-Off in DECK May Be Overdone
- Verizon’s Q3 Results Show Why SpaceX’s Spectrum Grab Isn’t a Major Threat
- Comfort Systems Earnings: AI Slowdown or More Growth Ahead?
- Bristol Myers Squibb’s Cancer Breakthrough Could Have Implications Beyond Its Own Stock
Receive News & Ratings for Standard BioTools Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Standard BioTools and related companies with MarketBeat.com's FREE daily email newsletter.
